{
    "id": 675,
    "fullName": "NOTCH1 I1680N",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "NOTCH1 I1680N lies within the HD-C domain of the Notch1 protein (PMID: 16738328). I1680N (reported as I1681N) results in activation of Notch1 signaling, including ligand-independent activation as indicated in a reporter assay, increased S2 and S3 proteolytic cleavage of Notch1, and altered heterodimer stability (PMID: 16738328).",
            "references": [
                {
                    "id": 2752,
                    "pubMedId": 16738328,
                    "title": "Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16738328"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4851,
        "geneSymbol": "NOTCH1",
        "terms": [
            "NOTCH1",
            "AOS5",
            "AOVD1",
            "hN1",
            "TAN1"
        ]
    },
    "variant": "I1680N",
    "createDate": "06/06/2014",
    "updateDate": "08/20/2019",
    "referenceTranscriptCoordinates": {
        "id": 143366,
        "transcript": "NM_017617",
        "gDna": "chr9:g.136503310A>T",
        "cDna": "c.5039T>A",
        "protein": "p.I1680N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21017,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth in a patient-derived xenograft model of adenoid cystic carcinoma harboring NOTCH1 I1680N (PMID: 27870570).",
            "molecularProfile": {
                "id": 778,
                "profileName": "NOTCH1 I1680N"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 778,
            "profileName": "NOTCH1 I1680N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 143366,
            "transcript": "NM_017617",
            "gDna": "chr9:g.136503310A>T",
            "cDna": "c.5039T>A",
            "protein": "p.I1680N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}